ストックスクリーナーアプリを入手
1.63
4.49%
0.07
アフターアワーズ：
1.63
前日終値:
$1.56
開ける：
$1.56
24時間の取引高:
405.99K
Relative Volume:
0.34
時価総額：
$109.80M
収益：
$488.00K
当期純損益:
$-41.44M
株価収益率:
-1.7527
EPS:
-0.93
ネットキャッシュフロー:
$-31.47M
1週間 パフォーマンス:
+3.16%
1か月 パフォーマンス:
-43.40%
6か月 パフォーマンス:
-29.13%
1年 パフォーマンス:
-65.90%
1日の値動き範囲:
$1.5493
$1.65
1週間の範囲:
$1.5493
$1.68
52週間の値動き範囲:
$1.48
$4.99
Cardiff Oncology Inc Stock (CRDF) Company Profile
名前
Cardiff Oncology Inc
セクター
電話
858-952-7570
住所
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.63 | 105.08M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.27 | 119.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.38 | 83.75B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
847.26 | 52.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.37 | 44.12B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
354.48 | 39.73B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | 開始されました | Noble Capital Markets | Outperform |
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2025-06-24 | 開始されました | Jefferies | Hold |
| 2024-09-06 | 開始されました | Craig Hallum | Buy |
| 2022-01-05 | 開始されました | William Blair | Outperform |
| 2021-12-08 | 開始されました | Robert W. Baird | Outperform |
| 2021-08-09 | 再開されました | Maxim Group | Buy |
| 2020-10-22 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-08 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Cardiff Oncology Inc (CRDF) 最新ニュース
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewswire
Why Cardiff Oncology Inc. (XE7C) stock could be next leaderWeekly Trend Recap & Growth Focused Stock Reports - mfd.ru
Can Cardiff Oncology Inc. stock reach $100 price targetMarket Activity Recap & Safe Entry Trade Signal Reports - mfd.ru
Will Cardiff Oncology Inc. stock outperform tech sector in 2025Weekly Stock Report & Free Community Supported Trade Ideas - mfd.ru
Will Cardiff Oncology Inc. outperform its industry peersQuarterly Portfolio Report & Precise Buy Zone Identification - mfd.ru
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
CRDF: New CEO Presents Phase II Readout - Yahoo Finance
Will Cardiff Oncology Inc. (XE7C) stock justify high valuationM&A Rumor & Growth Focused Entry Reports - mfd.ru
Leadership Turmoil Clouds Clinical Progress at Cardiff Oncology - AD HOC NEWS
Ideas Watch: Is Cardiff Oncology Inc likely to announce a buybackWeekly Gains Summary & Safe Entry Trade Reports - baoquankhu1.vn
Cardiff Oncology (CRDF) Is Down 43.9% After Advancing Onvansertib And Reshuffling Leadership Team - Yahoo Finance
Cardiff Oncology Faces Turbulence Amid Leadership Changes - StocksToTrade
CRDF: HC Wainwright & Co. Reiterates Buy Rating with $10 Price T - GuruFocus
H.C. Wainwright reiterates Buy rating on Cardiff Oncology stock at $10 - Investing.com Canada
Cardiff Oncology (CRDF) Stock Drop Presents New Investment Oppor - GuruFocus
Why Did Cardiff Oncology Stock Plunge On Tuesday?Cardiff Oncology (NASDAQ:CRDF) - Benzinga
Investors Buy High Volume of Cardiff Oncology Call Options (NASDAQ:CRDF) - Defense World
Cardiff Oncology appoints interim CEO amid leadership transition By Investing.com - Investing.com India
Cardiff To Pursue Narrower CRC Market For Onvansertib As Top Execs Step Down - Citeline News & Insights
Cardiff Oncology Overhauls Leadership to Advance Onvansertib - TipRanks
Favorite son in PLK1? Cardiff dips as phase II CRC bid advances - BioWorld MedTech
CEO transition at Cardiff Oncology (NASDAQ: CRDF) paired with positive Phase 2 trial - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Cardiff Oncology (CRDF) Shares Plunge After Executive Departures and Trial Update - GuruFocus
Cardiff Oncology Shares Plunge 35% Following CEO and CFO Resignations - Intellectia AI
Cardiff Oncology Sees Unusually Large Options Volume (NASDAQ:CRDF) - MarketBeat
Cardiff Oncology Taps Interim CEO, Picks 30mg Onvansertib Regimen for 2026 Registrational mCRC Study - MarketBeat
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development - The Globe and Mail
Cardiff Oncology down after leadership shakeup (CRDF:NASDAQ) - Seeking Alpha
Cardiff Oncology stock tumbles after Phase 2 trial data update By Investing.com - Investing.com Canada
Cardiff Oncology plunges after top executives step down - TradingView
Cardiff Oncology (CRDF) Reports Promising Phase 2 Trial Results - GuruFocus
Cardiff Oncology reports positive phase 2 data for cancer drug - Investing.com
Cardiff Oncology reports positive phase 2 data for cancer drug By Investing.com - Investing.com Nigeria
Cardiff Oncology (CRDF) Announces Leadership Changes - GuruFocus
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC - The Manila Times
Cardiff Oncology Announces Positive Phase 2 Trial Results for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer - Quiver Quantitative
Cardiff Oncology Announces Positive Update from its - GlobeNewswire
Guidance Update: Can SPAR Group Inc generate free cash flowJuly 2025 Pullbacks & Real-Time Market Sentiment Reports - baoquankhu1.vn
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update - ADVFN
CRDFTrovagene Presents Outlook for Second Half of 2018 - ADVFN
CRDF Stock Price, Forecast & Analysis | CARDIFF ONCOLOGY INC (NASDAQ:CRDF) - Chartmill
3 Promising Penny Stocks With Market Caps Below $600M - simplywall.st
How Cardiff Oncology Inc. stock benefits from tech adoptionMorning Star Patterns & Free Long-Term Investment Planning - bollywoodhelpline.com
Gains Recap: Should you buy the dip on Cardiff Oncology Inc2025 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
Will Cardiff Oncology Inc. benefit from sector rotationJuly 2025 Snapshot & Safe Entry Trade Reports - bollywoodhelpline.com
What hedge fund moves indicate for Cardiff Oncology Inc. (XE7C) stock2025 Sector Review & Weekly Setup with ROI Potential - Bollywood Helpline
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.13 Consensus Price Target from Brokerages - Defense World
Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm (NASDAQ:CRDF) - Seeking Alpha
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is Cardiff Oncology Inc. stock a buy for dividend growthJuly 2025 Action & Long Hold Capital Preservation Tips - Улправда
Cardiff Oncology Inc (CRDF) 財務データ
収益
当期純利益
現金流量
EPS
0.15%
1.22%
大文字化:
|
ボリューム (24 時間):